Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-7.51 Insider Own2.50% Shs Outstand54.22M Perf Week8.50%
Market Cap345.92M Forward P/E- EPS next Y-5.49 Insider Trans7.77% Shs Float53.09M Perf Month74.32%
Income-400.20M PEG- EPS next Q-1.70 Inst Own- Short Float41.40% Perf Quarter7.23%
Sales134.10M P/S2.58 EPS this Y-80.50% Inst Trans6.00% Short Ratio4.23 Perf Half Y-61.00%
Book/sh-1.60 P/B- EPS next Y23.50% ROA-52.50% Target Price16.81 Perf Year-57.69%
Cash/sh6.53 P/C0.98 EPS next 5Y35.10% ROE- 52W Range2.93 - 32.05 Perf YTD-64.48%
Dividend- P/FCF- EPS past 5Y-19.10% ROI-50.10% 52W High-80.09% Beta1.97
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin79.00% 52W Low117.75% ATR0.61
Employees468 Current Ratio3.80 Sales Q/Q64.90% Oper. Margin- RSI (14)69.63 Volatility15.41% 13.86%
OptionableYes Debt/Eq- EPS Q/Q-0.80% Profit Margin- Rel Volume1.02 Prev Close6.31
ShortableYes LT Debt/Eq- EarningsNov 07 BMO Payout- Avg Volume5.20M Price6.38
Recom2.60 SMA2055.28% SMA5050.62% SMA200-54.92% Volume5,362,715 Change1.11%
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Nov-14-19 01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
Nov-13-19 05:51AM  Edited Transcript of CLVS earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents +19.85%
04:00AM  Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy Business Wire
Nov-11-19 10:29AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks -8.50%
Nov-08-19 10:49AM  Were Hedge Funds Right About Dumping Clovis Oncology Inc (CLVS)? Insider Monkey +36.11%
09:32AM  Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
Nov-07-19 09:25AM  Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates Zacks +20.50%
08:00AM  Clovis Oncology Announces Third Quarter 2019 Operating Results Business Wire
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Oct-31-19 10:34AM  Analysts Estimate Clovis Oncology (CLVS) to Report a Decline in Earnings: What to Look Out for Zacks -6.76%
Oct-22-19 08:30AM  Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7 Business Wire
Oct-11-19 09:19AM  Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund Business Wire
Oct-09-19 11:22AM  Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook Zacks
Oct-08-19 11:08AM  Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks Benzinga -12.22%
Oct-04-19 10:31AM  J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug Zacks
Oct-02-19 07:47AM  Is Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Fair? Simply Wall St.
Sep-30-19 09:00AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Sep-29-19 02:30AM  Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019 Business Wire
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 02:08PM  Clovis Oncology Call Volume Spikes After Downgrade Schaeffer's Investment Research -6.87%
11:36AM  Clovis Gains Rights to Pre-Clinical Cancer Program for $12M Zacks
08:58AM  Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed Barrons.com
08:12AM  The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger Benzinga
Sep-23-19 04:00AM  Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals Business Wire
Sep-12-19 04:00AM  Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019 Business Wire -5.31%
Sep-04-19 06:00AM  Near an All-Time Low, Is Clovis Oncology a Buy? Motley Fool
Aug-31-19 09:32AM  Why Is Clovis (CLVS) Down 36.8% Since Last Earnings Report? Zacks
Aug-28-19 08:05AM  Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference Business Wire
Aug-22-19 05:42PM  Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024 Business Wire
Aug-19-19 10:15AM  Clovis Oncology Inc (CLVS) President and CEO Patrick J Mahaffy Bought $279,500 of Shares GuruFocus.com +6.25%
Aug-18-19 10:18AM  Who Has Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.
Aug-13-19 10:58AM  AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis Benzinga
Aug-08-19 11:56PM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool -35.01%
06:26PM  Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Business Wire
Aug-07-19 04:10PM  Clovis Oncology to Offer $225 Million of Convertible Senior Notes Business Wire
Aug-06-19 07:58PM  Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.32%
Aug-02-19 10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
06:24AM  Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 01:11PM  Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today Motley Fool -15.92%
Jul-25-19 10:33AM  Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-24-19 09:00AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-18-19 08:00AM  Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1 Business Wire -6.16%
Jul-16-19 10:51AM  Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study Zacks
Jul-12-19 03:18PM  Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price? Simply Wall St.
Jul-02-19 08:37AM  Do Options Traders Know Something About Clovis (CLVS) Stock We Don't? Zacks -5.99%
Jun-24-19 08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks -11.30%
Jun-18-19 08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
Jun-13-19 11:51AM  Is Clovis Oncology Inc (CLVS) A Good Stock To Buy? Insider Monkey
Jun-07-19 07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 04:05PM  Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair Business Wire
09:31AM  Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report? Zacks
Jun-01-19 07:30AM  Expanded Rubraca® (Rucaparib) Data from Clovis Oncologys ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting Business Wire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
10:08AM  Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales Barrons.com
May-20-19 04:05PM  Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca® in Advanced Ovarian Cancer Business Wire
May-16-19 08:00AM  Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting Business Wire
May-15-19 10:40PM  Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-08-19 09:46AM  Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks
05:23AM  Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 09:15AM  Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:09AM  Clovis: 1Q Earnings Snapshot Associated Press
08:00AM  Clovis Oncology Announces First Quarter 2019 Operating Results Business Wire
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
03:06PM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
11:42AM  Cronos (CRON) to Report Q1 Earnings: What's in the Cards? Zacks
08:00AM  Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019 Business Wire
May-03-19 10:12AM  Heres What Hedge Funds Think About About Clovis Oncology Inc (CLVS) Insider Monkey
May-02-19 08:00AM  Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million Business Wire
Apr-30-19 10:32AM  Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-25-19 02:58PM  What Are Analysts Saying About The Future Of Clovis Oncology, Inc.'s (NASDAQ:CLVS)? Simply Wall St.
Apr-24-19 04:05PM  Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7 Business Wire
Apr-18-19 11:29AM  Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks
Apr-16-19 10:38AM  Company News For Apr 16, 2019 Zacks
Apr-15-19 04:37PM  Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment InvestorPlace -12.48%
03:31PM  Here's Why Clovis Oncology Stock Dropped as Much as 13% Today Motley Fool
12:36PM  Analysts, Options Traders Swarm Sinking CLVS Stock Schaeffer's Investment Research
09:57AM  Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks
Apr-12-19 06:02PM  Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report MarketWatch
05:46PM  Clovis Oncology, Conduent, Edison International and More: Heres What The Smart Money Thinks of These Market Movers Insider Monkey
05:37PM  Clovis Oncology halts mid-stage bladder cancer trial, shares drop Reuters
Apr-10-19 10:14AM  AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks
Apr-03-19 10:22AM  Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks
Apr-02-19 09:44AM  Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks
08:30AM  Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019 Business Wire
Apr-01-19 08:44AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks
Mar-28-19 09:30AM  Why Is Clovis (CLVS) Down 21% Since Last Earnings Report? Zacks
Mar-19-19 08:00AM  Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting Business Wire
Mar-16-19 12:45PM  Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress Business Wire
Mar-07-19 02:07PM  Did Changing Sentiment Drive Clovis Oncologys Share Price Down A Worrying 66%? Simply Wall St.
Mar-06-19 04:19PM  Clovis Oncology to Present at the Barclays Global Healthcare Conference Business Wire -5.31%
07:00AM  New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 03:00AM  Clovis Oncology Announces Availability of Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany Business Wire
Mar-01-19 06:39AM  Edited Transcript of CLVS earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 05:43PM  Here's Why Clovis Oncology Stock Jumped on Wednesday Motley Fool +13.17%
08:12AM  Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover Zacks
07:15AM  AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study Zacks
12:46AM  Clovis Oncology Inc (CLVS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 08:00AM  Clovis Oncology Announces 2018 Operating Results Business Wire
06:30AM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-19 08:00AM  Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference Business Wire
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksSep 20Sale4.808374,018193,509Sep 24 04:46 PM
Rolfe LindseySee RemarksSep 20Sale4.801,7448,37123,881Sep 24 04:45 PM
Rolfe LindseySee RemarksSep 04Sale5.217163,73021,875Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksSep 04Sale5.214952,5798,772Sep 06 04:45 PM
Gross Paul EdwardSee RemarksSep 04Sale5.214952,5795,642Sep 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksSep 04Sale5.216303,282192,113Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksAug 27Sale6.092391,4568,528Aug 28 04:15 PM
ATWOOD BRIAN GDirectorAug 20Option Exercise0.2925,8627,50025,862Aug 22 04:15 PM
BLAIR JAMES CDirectorAug 20Buy5.9720,000119,40020,000Aug 20 09:49 PM
BLAIR JAMES CDirectorAug 16Buy5.7020,000114,00033,439Aug 20 09:49 PM
MAHAFFY PATRICK JPresident and CEOAug 16Buy5.5950,000279,576968,787Aug 19 08:35 AM
SPICKSCHEN THORLEFDirectorAug 16Buy5.678,60048,76258,176Aug 16 05:45 PM
SPICKSCHEN THORLEFDirectorAug 14Buy5.469,20050,23249,576Aug 15 04:12 PM
KLINGENSTEIN PAUL HDirectorJul 29Option Exercise0.2925,8627,50059,327Jul 31 04:24 PM
Rolfe LindseySee RemarksJun 20Sale14.701,72825,40221,591Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 20Sale14.7082912,186191,788Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 04Sale15.075778,695190,357Jun 06 04:48 PM
MUEHL DANIEL WSee RemarksJun 04Sale15.074536,8277,905Jun 06 04:46 PM
Gross Paul EdwardSee RemarksJun 04Sale15.074536,8274,001Jun 06 04:45 PM
Rolfe LindseySee RemarksJun 04Sale15.076559,87119,537Jun 06 04:45 PM
MUEHL DANIEL WSee RemarksMay 29Sale14.882714,0327,643May 31 05:01 PM
IVERS-READ GILLIAN CSee RemarksMar 20Sale26.1383021,688190,007Mar 21 05:00 PM
Rolfe LindseySee RemarksMar 20Sale26.131,72945,17919,224Mar 21 04:57 PM
BLAIR JAMES CDirectorMar 14Sale27.7917,056473,9860Mar 18 04:53 PM
Gross Paul EdwardSee RemarksMar 05Sale29.291,32538,8092,577Mar 06 04:47 PM
IVERS-READ GILLIAN CSee RemarksMar 05Sale29.291,61147,186187,507Mar 06 04:47 PM
Rolfe LindseySee RemarksMar 05Sale29.291,73150,70116,176Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksMar 05Sale29.291,29737,9896,177Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksFeb 27Sale25.902666,8895,945Feb 28 06:25 PM
SPICKSCHEN THORLEFDirectorJan 03Option Exercise0.8832,75828,74040,376Jan 03 04:45 PM
Rolfe LindseySee RemarksDec 20Sale17.721,72830,62015,872Dec 26 09:00 AM
IVERS-READ GILLIAN CSee RemarksDec 20Sale17.7282914,690187,198Dec 26 09:00 AM
Rolfe LindseySee RemarksDec 04Sale21.232846,02914,162Dec 06 05:05 PM
MUEHL DANIEL WSee RemarksDec 04Sale21.231883,9915,664Dec 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksDec 04Sale21.232505,308186,152Dec 06 04:45 PM